References

farmaec

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология

2070-49092070-4933

IRBIS LLC

10.17749/2070-4909/farmakoekonomika.2023.215

farmaec-948

Research Article

ORIGINAL ARTICLES

ОРИГИНАЛЬНЫЕ ПУБЛИКАЦИИ

Nephroprotective peptides of Laennec® in the context of pharmacotherapy for nephro-hepato-metabolic disorders

Нефропротекторные пептиды препарата Лаеннек® в контексте фармакотерапии нефрогепатометаболических нарушений

https://orcid.org/0000-0002-7663-710X

Громова

О. А.

Gromova

O. A.

д.м.н., профессор, ведущий научный сотрудник

WoS ResearcherID: J-4946-2017; Scopus Author ID: 7003589812

ул. Вавилова, д. 44, корп. 2, Москва 119333, Россия

Dr. Med. Sc., Professor, Leading Researcher

WoS ResearcherID: J-4946-2017; Scopus Author ID: 7003589812

44 corp. 2 Vavilov Str., Moscow 119333, Russia

unesco.gromova@gmail.com

https://orcid.org/0000-0002-2659-7998

Торшин

И. Ю.

Torshin

I. Yu.

к.ф-м.н., к.х.н., ведущий научный сотрудник

WoS ResearcherID: C-7683-2018; Scopus Author ID: 7003300274

ул. Вавилова, д. 44, корп. 2, Москва 119333, Россия

PhD (Phys. Math.), PhD (Chem.), Leading Researcher

WoS ResearcherID: C-7683-2018; Scopus Author ID: 7003300274

44 corp. 2 Vavilov Str., Moscow 119333, Russia

https://orcid.org/0000-0001-7507-191X

Громов

А. Н.

Gromov

A. N.

инженер-исследователь

WoS ResearcherID: C-7476-2018; Scopus Author ID: 7102053964;

ул. Вавилова, д. 44, корп. 2, Москва 119333, Россия

Research Engineer

WoS ResearcherID: C-7476-2018; Scopus Author ID: 7102053964

44 corp. 2 Vavilov Str., Moscow 119333, Russia

https://orcid.org/0000-0002-2810-566X

Тихонова

О. В.

Tikhonova

O. V.

к.б.н., руководитель ЦКП «Протеом человека»

WoS ResearcherID: F-5115-2017; Scopus Author ID: 57189102916

ул. Погодинская, д. 10, стр. 8, Москва 119121, Россия

PhD (Biol.), Head of Center for Collective Use “Human Proteome”

WoS ResearcherID: F-5115-2017; Scopus Author ID: 57189102916

10 bldg 8 Pogodinskaya Str., Moscow 119121, Russia

Федеральный исследовательский центр «Информатика и управление» Российской академии наукРоссияFederal Research Center “Computer Science and Control”, RASRussian Federation

Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт биомедицинской химии им. В.Н. Ореховича»РоссияOrekhovich Research Institute of Biomedical ChemistryRussian Federation

2023

18122023

164570586

2024

Громова О.А., Торшин И.Ю., Громов А.Н., Тихонова О.В.

Gromova O.A., Torshin I.Y., Gromov A.N., Tikhonova O.V.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.pharmacoeconomics.ru/jour/article/view/948

Background. Renal-hepatic dysfunction, which often occurs in liver dysfunction, requires the use of effective and safe nephroprotective agents. Human placenta hydrolysates (HPH) are hepatoprotectors, but little is known about HPH nephroprotective properties and the molecular mechanisms of their implementation.Objective: identification of potential molecular mechanisms of Laennec® HPH neuroprotective action based on bioinformatic analysis of collected mass spectrometric data.Material and methods. Methods of proteomic analysis of peptide preparations were used. The analysis of Laennec® HPH peptide composition included four stages: drug purification, chromatographic separation of peptides, determination of the multidimensional mass spectrum of peptide fraction and de novo sequencing of the isolated peptides.Results. The study of Laennec® HPH peptide composition allowed to identify 48 peptides that can exhibit nephroprotective effects. It was shown that HPH contains biologically active fragments of nephroprotective adrenomedullins, inhibitor peptides of a number of kinases (FYN, SHH, WNK1/4, SGK1, IRAK4, ROCK1/2) and fibrogenic receptors (PDGFR, TGFB1I1).Conclusion. By inhibiting the listed target proteins, HPH peptides provide nephroprotection through reducing inflammation, anti-stress effects and preventing fibrotic changes in kidney tissue

Актуальность. Почечно-печеночная дисфункция, часто возникающая на фоне нарушений функции печени, требует использования эффективных и безопасных нефропротекторных средств. Гидролизаты плаценты человека (ГПЧ) являются гепатопротекторами, при этом нефропротекторные свойства ГПЧ и молекулярные механизмы их реализации малоизвестны.Цель: выявление потенциальных молекулярных механизмов нефропротекторного действия ГПЧ Лаеннек® на основании биоинформационного анализа собранных масс-спектрометрических данных.Материал и методы. Использовались методы протеомного анализа пептидных препаратов. Анализ пептидного состава ГПЧ Лаеннек® включал четыре этапа: очистка препарата, хроматографическое разделение пептидов, определение многомерного масс-спектра пептидной фракции и de novo секвенирование выделенных пептидов.Результаты. Исследование пептидного состава ГПЧ Лаеннек® позволило выявить 48 пептидов, которые могут оказывать нефропротекторные эффекты. Показано, что ГПЧ содержит биологически активные фрагменты нефропротекторных адреномедуллинов, пептиды – ингибиторы ряда киназ (FYN, SHH, WNK1/4, SGK1, IRAK4, ROCK1/2) и фиброгенных рецепторов (PDGFR, TGFB1I1).Заключение. Ингибируя перечисленные таргетные белки, пептиды ГПЧ осуществляют нефропротекцию через снижение воспаления, антистрессорные эффекты и предотвращение фибротических изменений ткани почек.

Нефропротекциягепатопротекциядетоксикацияфиброзвоспалениестандартизированный гидролизат плаценты человека

Nephroprotectionhepatoprotectiondetoxificationfibrosisinflammationstandardized human placenta hydrolysate

References1

Ермоленко В.М., Николаев А.Ю. Острая почечная недостаточность. М.: ГЭОТАР-Медиа; 2010: 240 с.

Ermolenko V.M., Nikolaev A.Yu. Acute renal failure. Moscow: GEOTAR-Media; 2010: 240 pp. (in Russ.).

Arroyo V. The liver and the kidney: mutual clearance or mixed intoxication. Contrib Nephrol. 2007; 156: 17–23. https://doi.org/10.1159/000102011.

Mookerjee R.P., Malaki M., Davies N.A., et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology. 2007; 45 (1): 62–71. https://doi.org/10.1002/hep.21491.

Shoji T., Wada A., Inoue K., et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract. 2007; 105 (3): c99–107. https://doi.org/10.1159/000097985.

Baquerizo A., Anselmo D., Shackleton C., et al. Phosphorus ans an early predictive factor in patients with acute liver failure. Transplantation. 2003; 75 (12): 2007–14. https://doi.org/10.1097/01.TP.0000063219.21313.32.

Fraunberger P., Wang Y., Holler E., et al. Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever. Shock. 2006; 26 (1): 10–2. https://doi.org/10.1097/01.shk.0000215319.06866.bd.

Lane K., Dixon J.J., MacPhee I.A., Philips B.J. Renohepatic crosstalk: does acute kidney injury cause liver dysfunction? Nephrol Dial Transplant. 2013; 28 (7): 1634-47. https://doi.org/10.1093/ndt/gft091.

Fisher E.S., Curry S.C. Evaluation and treatment of acetaminophen toxicity. Adv Pharmacol. 2019; 85: 263–72. https://doi.org/10.1016/bs.apha.2018.12.004.

Avci E., Abasiyanik F. Autoimmune hepatitis after SARS-CoV-2 vaccine: new-onset or flare-up? J Autoimmun. 2021; 125: 102745. https://doi.org/10.1016/j.jaut.2021.102745.

Silva-Aguiar R.P., Teixeira D.E., Peres R.A.S., et al. Subclinical acute kidney injury in COVID-19: possible mechanisms and future perspectives. Int J Mol Sci. 2022; 23 (22): 14193. https://doi.org/10.3390/ijms232214193.

Yende S., Parikh C.R. Long COVID and kidney disease. Nat Rev Nephrol. 2021; 17 (12): 792–3. https://doi.org/10.1038/s41581-021-00487-3.

Ghonaim A.H., Hopo M.G., Ismail A.K., et al. Hepatoprotective and renoprotective effects of silymarin against salinomycin-induced toxicity in adult rabbits. Vet World. 2022; 15 (9): 2244–52. https://doi.org/10.14202/vetworld.2022.2244-2252.

Feng J., Gao H., Yang L., et al. Renoprotective and hepatoprotective activity of Lepidiumdraba L. extracts on oxymetholone-induced oxidative stress in rat. J Food Biochem. 2022; 46 (9): e14250. https://doi.org/10.1111/jfbc.14250.

Adeoye S.W.A., Adeshina O.S., Yusuf M.G., Omole A. Hepatoprotective and renoprotective effect of moringa oleifera seed oil on dichlorvos-induced toxicity in male Wistar rats. Niger J Physiol Sci. 2022; 37 (1): 119–26. https://doi.org/10.54548/njps.v37i1.15.

Mirmohammadlu M., Hosseini S.H., Kamalinejad M., et al. Hypolipidemic, hepatoprotective and renoprotective effects of Cydonia oblonga Mill. Fruit in streptozotocin-induced diabetic rats. Iran J Pharm Res. 2015; 14 (4): 1207–14.

Громова О.А., Торшин И.Ю., Чучалин А.Г., Максимов В.А. Гидролизаты плаценты человека: от В.П. Филатова до наших дней. Терапевтический архив. 2022; 94 (3): 434–41. https://doi.org/10.26442/00403660.2022.03.201408.

Gromova O.A., Torshin I.Yu., Chuchalin A.G., Maksimov V.A. Human placenta hydrolysates: from V.P. Filatov to the present day. Terapevticheskii Arkhiv / Therapeutic Archive. 2022; 94 (3): 434–41. https://doi.org/10.26442/00403660.2022.03.201408.

Громова О.А., Торшин И.Ю., Демидов В.И. и др. Экспериментальный лекарственный гепатит. Гепатопротекторные эффекты препарата Лаеннек на моделях токсического повреждения печени парацетамолом или алкоголем. Экспериментальная и клиническая гастроэнтерология. 2022; 3: 86–92. https://doi.org/10.31146/1682-8658-ecg-199-3-86-92.

Gromova O.A., Torshin I.Yu., Demidov V.I., et al. Experimental medicinal hepatitis. Hepatoprotective effects of the drug Laennec in models of toxic liver injury with paracetamol or alcohol. Experimental and Clinical Gastroenterology. 2022; 3: 86–92 (in Russ.). https://doi.org/10.31146/1682-8658-ecg-199-3-86-92.

Торшин И.Ю., Громова О.А., Тихонова О.В., Згода В.Г. Гепатопротекторные пептиды препарата Лаеннек. Экспериментальная и клиническая гастроэнтерология. 2022; 7: 21–30. https://doi.org/10.31146/1682-8658-ecg-203-7-21-3019.

Torshin I.Yu., Gromova O.A., Tikhonova O.V., Zgoda V.G. Hepatoprotective peptides of the drug Laennec. Experimental and Clinical Gastroenterology. 2022; 7: 21–30 (in Russ.). https://doi.org/10.31146/1682-8658-ecg-203-7-21-30.

Громова О.А., Торшин И.Ю., Максимов В.А. и др. Пептиды в составе препарата Лаеннек, способствующие устранению гиперферритинемии и перегрузки железом. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (4): 413–25. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.070.

Gromova O.A., Torshin I.Yu., Maksimov V.A., et al. Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (4): 413–25 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.070.

Torshin I.Y., Rudakov K.V. On the application of the combinatorial theory of solvability to the analysis of chemographs. Part 1: Fundamentals of modern chemical bonding theory and the concept of the chemograph. Pattern Recognit Image Anal. 2014; 24 (1): 11–23. https://doi.org/10.1134/S1054661814010209.

Torshin I.Y., Rudakov K.V. On the application of the combinatorial theory of solvability to the analysis of chemographs.Part 1: Fundamentals of modern chemical bonding theory and the concept of the chemograph. Pattern Recognit Image Anal. 2014; 24 (1): 11–23. https://doi.org/10.1134/S1054661814010209.

Torshin I.Yu., Rudakov K.V. On the procedures of generation of numerical features over partitions of sets of objects in the problem of predicting numerical target variables. Pattern Recognit Image Anal. 2019; 29 (4): 654–67. https://doi.org/10.1134/S1054661819040175.

Takahashi K., Hirose T., Mori N., et al. The renin-angiotensin system, adrenomedullins and urotensin II in the kidney: possible renoprotection via the kidney peptide systems. Peptides. 2009; 30 (8): 1575–85. https://doi.org/10.1016/j.peptides.2009.05.018.

Ito K., Yoshii H., Asano T., et al. Adrenomedullin increases renal nitric oxide production and ameliorates renal injury in mice with unilateral ureteral obstruction. J Urol. 2010; 183 (4): 1630–5. https://doi.org/10.1016/j.juro.2009.12.002.

Smith D.M., Coppock H.A., Withers D.J., et al. Adrenomedullin: receptor and signal transduction. Biochem Soc Trans. 2002; 30 (4): 432–7. https://doi.org/10.1042/bst0300432.

Buhl E.M., Djudjaj S., Klinkhammer B.M., et al. Dysregulated mesenchymal PDGFR-β drives kidney fibrosis. EMBO Mol Med. 2020; 12 (3): e11021. https://doi.org/10.15252/emmm.201911021.

Naba A., Reverdy C., Louvard D., Arpin M. Spatial recruitment and activation of the Fes kinase by ezrin promotes HGF-induced cell scattering. EMBO J. 2008; 27 (1): 38–50. https://doi.org/10.1038/sj.emboj.7601943.

Ozdamar B., Bose R., Barrios-Rodiles M., et al. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science. 2005; 307 (5715): 1603–9. https://doi.org/10.1126/science.1105718.

Wu J.C., Wang X.J., Zhu J.H., et al. GPR97 deficiency ameliorates renal interstitial fibrosis in mouse hypertensive nephropathy. Acta Pharmacol Sin. 2023; 44 (6): 1206–16. https://doi.org/10.1038/s41401-022-01041-y.

Terashima H., Kato M., Ebisawa M., et al. R-268712, an orally active transforming growth factor-β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model. Eur J Pharmacol. 2014; 734: 60–6. https://doi.org/10.1016/j.ejphar.2014.03.045.

Saelzler M.P., Spackman C.C., Liu Y., et al. ERK8 down-regulates transactivation of the glucocorticoid receptor through Hic-5. J Biol Chem. 2006; 281 (24): 16821–32. https://doi.org/10.1074/jbc.M512418200.

Ryan P.E., Kales S.C., Yadavalli R., et al. Cbl-c ubiquitin ligase activity is increased via the interaction of its RING finger domain with a LIM domain of the paxillin homolog, Hic 5. PLoS One. 2012; 7 (11): e49428. https://doi.org/10.1371/journal.pone.0049428.

Mizuguchi T., Collod-Beroud G., Akiyama T., et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004; 36 (8): 855–60. https://doi.org/10.1038/ng1392.

Wieser R., Wrana J.L., Massagué J. GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J. 1995; 14 (10): 2199–208. https://doi.org/10.1002/j.1460-2075.1995.tb07214.x.

Ding H., Zhou D., Hao S., et al. Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. J Am Soc Nephrol. 2012; 23 (5): 801–13. https://doi.org/10.1681/ASN.2011060614.

Bosanac I., Maun H.R., Scales S.J., et al. The structure of SHH in complex with HHIP reveals a recognition role for the Shh pseudo active site in signaling. Nat Struct Mol Biol. 2009; 16 (7): 691–7. https://doi.org/10.1038/nsmb.1632.

Nanni L., Ming J.E., Bocian M., et al. The mutational spectrum of the sonic hedgehog gene in holoprosencephaly: SHH mutations cause a significant proportion of autosomal dominant holoprosencephaly. Hum Mol Genet. 1999; 8 (13): 2479–88. https://doi.org/10.1093/hmg/8.13.2479.

Scott D.C., Rhee D.Y., Duda D.M., et al. Two distinct types of E3 ligases work in unison to regulate substrate ubiquitylation. Cell. 2016; 166 (5): 1198–214.e24. https://doi.org/10.1016/j.cell.2016.07.027.

Shibata S., Zhang J., Puthumana J., et al. Kelch-like 3 and cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4. Proc Natl Acad Sci USA. 2013; 110 (19): 7838–43. https://doi.org/10.1073/pnas.1304592110.

Yue P., Zhang C., Lin D.H., et al. WNK4 inhibits Ca(2+)-activated big-conductance potassium channels (BK) via mitogen-activated protein kinase-dependent pathway. Biochim Biophys Acta. 2013; 1833 (10): 2101–10. https://doi.org/10.1016/j.bbamcr.2013.05.004.

Boyden L.M., Choi M., Choate K.A., et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature. 2012; 482 (7383): 98–102. https://doi.org/10.1038/nature10814.

Dephoure N., Zhou C., Villén J., et al. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA. 2008; 105 (31): 10762–7. https://doi.org/10.1073/pnas.0805139105.

Passos D.O., Bressan G.C., Nery F.C., Kobarg J. Ki-1/57 interacts with PRMT1 and is a substrate for arginine methylation. FEBS J. 2006; 273 (17): 3946–61. https://doi.org/10.1111/j.1742-4658.2006.05399.x.

Zhu Y., Yu C., Zhuang S. Protein arginine methyltransferase 1 mediates renal fibroblast activation and fibrogenesis through activation of Smad3 signaling. Am J Physiol Renal Physiol. 2020; 318 (2): F375–87. https://doi.org/10.1152/ajprenal.00487.2019.

Sakamaki J., Daitoku H., Ueno K., et al. Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt. Proc Natl Acad Sci USA. 2011; 108 (15): 6085–90. https://doi.org/10.1073/pnas.1015328108.

Bikkavilli R.K., Avasarala S., Vanscoyk M., et al. Dishevelled3 is a novel arginine methyl transferase substrate. Sci Rep. 2012; 2: 805. https://doi.org/10.1038/srep00805.

Weimann M., Grossmann A., Woodsmith J., et al. A Y2H-seq approach defines the human protein methyltransferase interactome. Nat Methods. 2013; 10 (4): 339–42. https://doi.org/10.1038/nmeth.2397.

Kentrup D., Reuter S., Schnöckel U., et al. Hydroxyfasudil-mediated inhibition of ROCK1 and ROCK2 improves kidney function in rat renal acute ischemia-reperfusion injury. PLoS One. 2011; 6 (10): e26419. https://doi.org/10.1371/journal.pone.0026419.

Edwards D.C., Sanders L.C., Bokoch G.M., Gill G.N. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1999; 1 (5): 253–9. https://doi.org/10.1038/12963.

Shao J., Welch W.J., Diprospero N.A., Diamond M.I. Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol. 2008; 28 (17): 5196–208. https://doi.org/10.1128/MCB.00079-08.

Ongusaha P.P., Qi H.H., Raj L., et al. Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal. 2008; 1 (47): ra14. https://doi.org/10.1126/scisignal.1161938.

Torres J., Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001; 276 (2): 993–8. https://doi.org/10.1074/jbc.M009134200.

Paule S., Aljofan M., Simon C., et al. Cleavage of endometrial α-integrins into their functional forms is mediated by proprotein convertase 5/6. Hum Reprod. 2012; 27 (9): 2766–74. https://doi.org/10.1093/humrep/des203.

Petra E., Siwy J., Vlahou A., Jankowski J. Urine peptidome in combination with transcriptomics analysis highlights MMP7, MMP14 and PCSK5 for further investigation in chronic kidney disease. PLoS One. 2022; 17 (1): e0262667. https://doi.org/10.1371/journal.pone.0262667.

Meriane M., Tcherkezian J., Webber C.A., et al. Phosphorylation of DCC by Fyn mediates Netrin-1 signaling in growth cone guidance. J Cell Biol. 2004; 167 (4): 687–98. https://doi.org/10.1083/jcb.200405053.

Dorotea D., Jiang S., Pak E.S., et al. Pan-Src kinase inhibitor treatment attenuates diabetic kidney injury via inhibition of Fyn kinasemediated endoplasmic reticulum stress. Exp Mol Med. 2022; 54 (8): 1086–97. https://doi.org/10.1038/s12276-022-00810-3.

Ishino M., Aoto H., Sasaski H., et al. Phosphorylation of Hic-5 at tyrosine 60 by CAKbeta and Fyn. FEBS Lett. 2000; 474 (2-3): 179–83. https://doi.org/10.1016/s0014-5793(00)01597-0.

Bai X.C., Yan C., Yang G., et al. An atomic structure of human γ-secretase. Nature. 2015; 525 (7568): 212–7. https://doi.org/10.1038/nature14892.

Juillerat-Jeanneret L., Flohr A., Schneider M., et al. Targeted γ-secretase inhibition to control the Notch pathway in renal diseases. J Med Chem. 2015; 58 (20): 8097–109. https://doi.org/10.1021/acs.jmedchem.5b00912.

Wiemuth D., Lott J.S., Ly K., et al. Interaction of serum- and glucocorticoid regulated kinase 1 (SGK1) with the WW-domains of Nedd4-2 is required for epithelial sodium channel regulation. PLoS One. 2010; 5 (8): e12163. https://doi.org/10.1371/journal.pone.0012163.

Wiemuth D., Lott J.S., Ly K., et al. Interaction of serumand glucocorticoid regulated kinase 1 (SGK1) with the WW-domains of Nedd4-2 is required for epithelial sodium channel regulation. PLoS One. 2010; 5 (8): e12163. https://doi.org/10.1371/journal.pone.0012163.

Voelkl J., Luong T.T., Tuffaha R., et al. SGK1 induces vascular smooth muscle cell calcification through NF-κB signaling. J Clin Invest. 2018; 128 (7): 3024–40. https://doi.org/10.1172/JCI96477.

Sierra-Ramos C., Velazquez-Garcia S., Keskus A.G., et al. Increased SGK1 activity potentiates mineralocorticoid/NaCl-induced kidney injury. Am J Physiol Renal Physiol. 2021; 320 (4): F628–43. https://doi.org/10.1152/ajprenal.00505.2020.

Donadei C., Angeletti A., Cantarelli C., et al. Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease. JCI Insight. 2019; 5 (10): e127428. https://doi.org/10.1172/jci.insight.127428.

Artunc F., Lang F. Mineralocorticoid and SGK1-sensitive inflammation and tissue fibrosis. Nephron Physiol. 2014; 128 (1-2): 35–9. https://doi.org/10.1159/000368267.

Zhuang L., Jin G., Hu X., et al. The inhibition of SGK1 suppresses epithelial-mesenchymal transition and promotes renal tubular epithelial cell autophagy in diabetic nephropathy. Am J Transl Res. 2019; 11 (8): 4946–56.

Tai D.J., Su C.C., Ma Y.L., Lee E.H. SGK1 phosphorylation of IkappaB kinase alpha and p300 up-regulates NF-kappaB activity and increases N-methyl-D-aspartate receptor NR2A and NR2B expression. J Biol Chem. 2009; 284 (7): 4073–89. https://doi.org/10.1074/jbc.M805055200.

Ozes O.N., Mayo L.D., Gustin J.A., et al. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999; 401 (6748): 82–5. https://doi.org/10.1038/43466.

Shi Y.H., Zhao S., Wang C., et al. Fluvastatin inhibits activation of JAK and STAT proteins in diabetic rat glomeruli and mesangial cells under high glucose conditions. Acta Pharmacol Sin. 2007; 28 (12): 1938–46. https://doi.org/10.1111/j.1745-7254.2007.00653.x.

Harada D., Yamanaka Y., Ueda K., et al. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1. Bone. 2007; 41 (2): 273–81. https://doi.org/10.1016/j.bone.2006.11.030.

Hörtner M., Nielsch U., Mayr L.M., et al. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur J Biochem. 2002; 269 (10): 2516–26. https://doi.org/10.1046/j.1432-1033.2002.02916.x.

Liu X., Wang L., Li H., et al. Coactivator-associated arginine methyltransferase 1 targeted by miR-15a regulates inflammation in acute coronary syndrome. Atherosclerosis. 2014; 233 (2): 349–56. https://doi.org/10.1016/j.atherosclerosis.2014.01.039.

Xu W., Chen H., Du K., et al. A transcriptional switch mediated by cofactor methylation. Science. 2001; 294 (5551): 2507–11. https://doi.org/10.1126/science.1065961.

Hoarau C., Gérard B., Lescanne E., et al. TLR9 activation induces normal neutrophil responses in a child with IRAK-4 deficiency: involvement of the direct PI3K pathway. J Immunol. 2007; 179 (7): 4754–65. https://doi.org/10.4049/jimmunol.179.7.4754.

Yamamoto T., Tsutsumi N., Tochio H., et al. Functional assessment of the mutational effects of human IRAK4 and MyD88 genes. Mol Immunol. 2014; 58 (1): 66–76. https://doi.org/10.1016/j.molimm.2013.11.008.

Kondo M., Tahara A., Hayashi K., et al. Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387 (10): 909–19. https://doi.org/10.1007/s00210-014-1023-z.

George J., Motshwene P.G., Wang H., et al. Two human MYD88 variants, S34Y and R98C, interfere with MyD88-IRAK4-myddosome assembly. J Biol Chem. 2011; 286 (2): 1341–53. https://doi.org/10.1074/jbc.M110.159996.

The authors declare that there are no conflicts of interest present.